Nobivac DHP vet.
Active substance
ATC code
Species
Dogs.
Indications
For the active immunisation of dogs to reduce clinical signs of disease caused by canine distemper virus infection; to prevent clinical signs and viral excretion caused by canine parvovirus infection; to reduce clinical signs of canine contagious hepatitis and viral excretion due to canine adenovirus 1 infection and to reduce clinical signs of respiratory infection and viral excretion caused by adenovirus type 2 infection.
Onset of immunity: 1 week.
Duration of immunity: 3 years.
Dose to be administered and administration route
The contents of one vial of reconstituted vaccine should be injected subcutaneously. Reconstitute immediately prior to use by the addition of the contents of one vial (1.0 ml) of the solvent provided or the vaccines in the Nobivac range against rabies or leptospirosis as mentioned in section 3.8 (where these products are authorised). Sterile equipment should be used for administration.
Avoid contamination of vaccine with traces of chemical sterilising agents. Do not use chemicals such as disinfectant or spirit to disinfect the skin prior to inoculation.
Vaccination regime
Primary course vaccination:
A single injection should establish active immunity in dogs of 10 weeks of age or older. Where earlier protection is required a first dose may be given to puppies from 6 weeks of age, but because maternally derived passive antibody can interfere with the response to vaccination a final dose should be given 2–4 weeks later i.e. at 10 weeks of age or older.
Booster vaccination:
To maintain protection a single booster dose is recommended every three years.
Reconstituted product: off-pink or pink coloured suspension.
Adverse reactions
Dogs:
|
Common (1 to 10 animals / 100 animals |
Injection site swelling1. |
|
treated): |
|
|
Rare (1 to 10 animals / 10,000 animals treated): |
Elevated temperature2. Hypersensitivity reaction (e.g. lethargy, facial oedema, pruritus, dyspnoea, vomiting, diarrhoea or collapse, including anaphylaxis)2. |
1 Up to 5 mm in diameter. This swelling may be hard and painful and last for up to 3 days post injection.
2 Transient.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
TRUSTED SOURCE
